Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Center, Korea
University of Kentucky
Eastern Cooperative Oncology Group
City of Hope Medical Center
Janssen Research & Development, LLC
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
National Cancer Institute (NCI)
University of Southern California
University of Chicago
First Affiliated Hospital of Wenzhou Medical University
Centre Francois Baclesse
Hospital Centre Biel/Bienne
National Institutes of Health Clinical Center (CC)
UNICANCER
Fox Chase Cancer Center
Bruckner Oncology
University of Florida
Albert Einstein College of Medicine
Radiation Therapy Oncology Group
M.D. Anderson Cancer Center
University of Cincinnati
Hirschfeld Oncology
University of Bern
Eastern Cooperative Oncology Group
University of Kansas Medical Center
Mayo Clinic
UroGen Pharma Ltd.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
M.D. Anderson Cancer Center
UNICANCER
Institute of Cancer Research, United Kingdom
Radiation Therapy Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
ChineseAMS
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
UroGen Pharma Ltd.
Seoul National University Hospital
Japan Clinical Oncology Group
Seoul National University Hospital
IRCCS San Raffaele
University of Michigan Rogel Cancer Center
Centro Nacional de Investigaciones Oncologicas CARLOS III
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)